Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy

This article has been Reviewed by the following groups

Read the full article

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an ongoing global human health crisis and will likely become endemic, requiring novel sustainable therapeutic strategies. We report on the discovery of a fully human multi-antibody cocktail (TATX-03) targeting diversified non-overlapping epitopes on the SARS-CoV-2 spike protein that suppressed replication-competent viral titers to undetectable levels in the lungs of SARS-CoV-2 challenged hamsters upon both prophylactic and therapeutic administration. While monotherapy with two of the individual cocktail components also showed clear in vivo protection, neither recapitulated the efficacy of TATX-03. This synergistic effect was further supported by examining in vivo efficacy of these individual antibodies and corresponding combination therapy at a lower dose. Furthermore, in vitro screenings using VSV-particles pseudo-typed with spike proteins representing the SARS-CoV-2 variants of concern Alpha, Beta, and Delta showed that TATX-03 maintained its neutralization potency. These results merit further development of TATX-03 as a potential therapy for SARS-CoV-2 infection with resistance to mutagenic escape.

Article activity feed

  1. SciScore for 10.1101/2021.07.20.452858: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsField Sample Permit: In vivo hamster challenge model of infection: All animal studies were performed at ViroClinics Xplore, Schaijk, The Netherlands and conducted according to European Union Directive 2010/63/EU and the standards of Dutch law for animal experimentation.
    Euthanasia Agents: On day 4 post-challenge all animals were euthanized by abdominal exsanguination under isoflurane anesthesia (3-5%).
    Sex as a biological variableBriefly, groups of five specific pathogen free (SPF) male Syrian golden hamsters (Mesocricetus auratus) aged 9 to 10 weeks at the start of the experiment were randomly assigned to experimental groups.
    RandomizationBriefly, groups of five specific pathogen free (SPF) male Syrian golden hamsters (Mesocricetus auratus) aged 9 to 10 weeks at the start of the experiment were randomly assigned to experimental groups.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    while full-length human IgG1 antibodies designated for in vitro neutralization and animal studies were produced in transiently transfected and/or stable CHO cells.
    human IgG1
    suggested: None
    Depletion panning with human ACE2- or CR3022-bound spike (where CR3022 represents an anti-SARS-CoV-1 antibody from the literature with cross-reactivity to SARS-CoV-223, 27) and irrelevant non-target proteins were performed to steer towards binders to specific epitopes and increase target specificity by reducing off-target reactivity, respectively.
    anti-SARS-CoV-1
    suggested: None
    SARS-CoV-223
    suggested: None
    After washing with PBS-T, appropriate HRP-conjugated secondary antibody (anti-M13 and goat-anti-human-IgG for detection of phages and full size hIgG1, repsectively) was added and incubated for 60 minutes at RT.
    anti-M13
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    In brief, HEK293-EBNA1 cells were transiently transfected with pUPE expression vectors containing recombinant protein encoding, codon-optimized synthetic genes.
    HEK293-EBNA1
    suggested: ATCC Cat# CRL-10852, RRID:CVCL_6974)
    Antibodies, expressed either as human IgG1-Fab and full-length human IgG1, destined for (initial) in vitro binding experiments were produced following transient transfection of HEK293 cells.
    HEK293
    suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)
    while full-length human IgG1 antibodies designated for in vitro neutralization and animal studies were produced in transiently transfected and/or stable CHO cells.
    CHO
    suggested: CLS Cat# 603479/p746_CHO, RRID:CVCL_0213)
    To induce expression of spike trimers in a cell context, HEK293F cells were transiently transfected using FectoPRO per the manufacturer specification (PolyPlus Transfection, Illkirch, France) with SARS-CoV-2 surface glycoprotein expression vector.
    HEK293F
    suggested: RRID:CVCL_6642)
    Briefly, the SARS-CoV-2 Spike protein was cloned into the pCAGGS expression vector system and transfected into HEK-293T cells.
    HEK-293T
    suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)
    Vero E6 monolayers are washed and incubated for 5 or 6 days at 37 °C.
    Vero E6
    suggested: None
    Recombinant DNA
    SentencesResources
    The fragments were ligated into the pHENIX-His8-VSV vector and transformed into Escherichia coli TG1 cells.
    pHENIX-His8-VSV
    suggested: None
    Briefly, the SARS-CoV-2 Spike protein was cloned into the pCAGGS expression vector system and transfected into HEK-293T cells.
    pCAGGS
    suggested: RRID:Addgene_18926)
    Software and Algorithms
    SentencesResources
    Library panning: The phage display libraries employed here were previously generated by ImmunoPrecise Antibodies (Naïve Human Library #0899
    Human Library
    suggested: None
    Heat maps were curated manually in Excel by merging the results from different experiments.
    Excel
    suggested: None
    EC50 values were calculated in GraphPad Prism.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • No funding statement was detected.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.